FDA Advisers Overlook Endpoint Concerns in Recommending Vanda’s Sleep Drug

Drug Industry Daily
A A
FDA advisers overwhelmingly voted Thursday to recommend approval of Vanda’s sleep drug tasimelteon for the visually impaired despite some concern over a clinical trial’s primary endpoint.

To View This Article:

Login

Subscribe To Drug Industry Daily